Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
6 hedge funds and large institutions have $104K invested in Lipella Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
200% more funds holding
Funds holding: 2 → 6 (+4)
132% more capital invested
Capital invested by funds: $44.7K → $104K (+$58.9K)
0.09% more ownership
Funds ownership: 0.03% → 0.12% (+0.09%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$32.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.42K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$137 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$39.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.86K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $72.3K | +$90.6K | +4,634 | New |
|
|
TSS
2
Two Sigma Securities
New York
| $25.6K | +$32.1K | +1,642 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $4K | +$5.42K | +277 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $1.58K | -$1.86K | -95 | -48% |
|
|
5
Fidelity Investments
Boston,
Massachusetts
| $100 | +$137 | +7 | New |
|
|
6
Wells Fargo
San Francisco,
California
| $16 | +$20 | +1 | New |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$39.8K | -1,564 | Closed |
|
LIPO Hedge Fund Activity: Q1 2023 in Review
6 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q1 2023, worth a combined $104K — up 132% from $44.7K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LIPO positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $90.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $39.8K sold.
- 6 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q1 2023, up from 2 in Q4 2022.
- Funds reported $104K of Lipella Pharmaceuticals stock for Q1 2023, up 132% quarter-over-quarter.
- 5 funds opened new Lipella Pharmaceuticals positions in Q1 2023 and 1 closed out, a net change of +4 holders.
- The largest Lipella Pharmaceuticals buyer in Q1 2023 was Vanguard Group, an estimated $90.6K added.
- The largest Lipella Pharmaceuticals seller in Q1 2023 was Citadel Advisors, an estimated $39.8K sold.
Based on aggregated 13F filings for Q1 2023.